Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ID: DRG0DOWMY)
ADC Name
WO2024230301A1 ADC-8
Synonyms
WO2024230301A1 ADC-8
   Click to Show/Hide
Organization
NOVACYTE THERAPEUTICS CO., LTD
Drug Status
Investigative
Drug-to-Antibody Ratio
7.3
Antibody Name
trastuzumab
  Antibody Info 
Antigen Name
Receptor tyrosine-protein kinase erbB-2 (HER2)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
Undisclosed
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 6 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (IC50)Human PBMC 
0.0181
nM
CVCL_0033
Breast adenocarcinoma
Half Maximal inhibitory Concentration (IC50)Human PBMC 
0.0184
nM
CVCL_1603
Gastric tubular adenocarcinoma
Half Maximal inhibitory Concentration (IC50)Human PBMC 
0.151
nM
CVCL_2077
Breast ductal carcinoma
Half Maximal inhibitory Concentration (IC50)Human PBMC 
1.6273
nM
CVCL_0031
Invasive breast carcinoma
Half Maximal Effective Concentration (EC50) 
1
nM
CVCL_0237
Pancreatic ductal adenocarcinoma
Half Maximal Effective Concentration (EC50) 
2.9
nM
CVCL_1483
Lung adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 6 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (IC50)Human PBMC 0.0181 nM Positive HER2 expression (HER2 +++/++)
Method Description
After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model Breast adenocarcinoma SK-BR-3 cells CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (IC50)Human PBMC 0.0184 nM High HER2 expression (HER2+++; >300,000 HER2 molecules/cell)
Method Description
After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model Gastric tubular adenocarcinoma NCI-N87 cells CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (IC50)Human PBMC 0.151 nM Positive HER2 expression (HER2 +++/++)
Method Description
After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model Breast ductal carcinoma JIMT-1 cells CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (IC50)Human PBMC 1.6273 nM Negative HER2 expression (HER2-)
Method Description
After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model Invasive breast carcinoma MCF-7 cells CVCL_0031
Experiment 5 Reporting the Activity Date of This ADC [2]
Efficacy Data Half Maximal Effective Concentration (EC50) 1 nM Low B7H3 expression (B7H3+)
Method Description
Cells were seeded (NCI-1650 or MDA-MB-453 (2E3/well) or Capan-1 (4E3/well)) into 3D 96-well plates (Corning: 4520), 80 ul/well, and incubated at 37 °C, 5% CO2, overnight.
In Vitro Model Pancreatic ductal adenocarcinoma Capan-1 cells CVCL_0237
Experiment 6 Reporting the Activity Date of This ADC [2]
Efficacy Data Half Maximal Effective Concentration (EC50) 2.9 nM High B7H3 expression (B7H3 +++)
Method Description
Cells were seeded (NCI-1650 or MDA-MB-453 (2E3/well) or Capan-1 (4E3/well)) into 3D 96-well plates (Corning: 4520), 80 ul/well, and incubated at 37 °C, 5% CO2, overnight.
In Vitro Model Lung adenocarcinoma NCI-H1650 cells CVCL_1483
References
Ref 1 An antibody-drug conjugate and its uses
Ref 2 Self-stabilizing linker conjugates